~~<i id='4BABE9AF23'><strike id='4BABE9AF23'><tt id='4BABE9AF23'><pre id='4BABE9AF23'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：fashion 2025-09-27 14:28:15 Page View：7893

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The Readout: Amylyx, Alumis, and Lundbeck drug updates
Next article： Alkermes shareholders re

Wikipedia

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

What will save rural psychiatry services? Higher Medicaid payments

AdobeIftherewereevertobeanemptybedinthestressunitmypsychiatristdadmanages,I’mcertainhewouldadmithims

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

CDC marks new Covid

ACovidtestingsiteinNewYorkCity.SpencerPlatt/GettyImagesPeoplewhoarenotuptodatewiththeirCovid-19vacci